Elevated plasma soluble sT2 is associated with heart failure symptoms and outcome in aortic stenosis

PLoS ONE

Volumn 10, Issue 9, 2015, Pages

  Lancellotti, Patrizio ^a,b   Dulgheru, Raluca ^a   Magne, Julien ^c   Henri, Christine ^a   Servais, Laurence ^a   Bouznad, Nassim ^a   Ancion, Arnaud ^a   Martinez, Christophe ^a   Davin, Laurent ^a   Le Goff, Caroline ^a   Nchimi, Alain ^a   Piérard, Luc ^a   Oury, Cécile ^a  

^a UNIVERSITY OF LIÈGE   (Belgium)

^b Research Ettore Sansavini Health Science Foundation   (Italy)

^c DUPUYTREN UNIVERSITY HOSPITAL   (France)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; BRAIN NATRIURETIC PEPTIDE; SOLUBLE ST2 PROTEIN; UNCLASSIFIED DRUG; CELL SURFACE RECEPTOR; IL1RL1 PROTEIN, HUMAN; INTERLEUKIN 1 RECEPTOR LIKE 1 PROTEIN;

AGED; AORTA STENOSIS; AORTA VALVE; ARTICLE; CARDIOVASCULAR MORTALITY; DISEASE ASSOCIATION; DISEASE SEVERITY; FEMALE; FOLLOW UP; HEART FAILURE; HEART LEFT VENTRICLE EJECTION FRACTION; HEART LEFT VENTRICLE ENDDIASTOLIC VOLUME; HEART LEFT VENTRICLE ENDSYSTOLIC VOLUME; HIGH RISK PATIENT; HUMAN; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; PROTEIN BLOOD LEVEL; AORTA VALVE STENOSIS; BLOOD; MIDDLE AGED; PATHOPHYSIOLOGY; VERY ELDERLY;

AGED; AGED, 80 AND OVER; AORTIC VALVE STENOSIS; FEMALE; HEART FAILURE; HUMANS; INTERLEUKIN-1 RECEPTOR-LIKE 1 PROTEIN; MALE; MIDDLE AGED; RECEPTORS, CELL SURFACE;

EID: 84946600704     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0138940     Document Type: Article

References (28)

1. Lancellotti P, Donal E, Magne J, Moonen M, O'Connor K, Daubert JC, et al. Risk stratification in asymptomatic moderate to severe aortic stenosis: the importance of the valvular, arterial and ventricular interplay. Heart. 2010; 96: 1364-71. doi: 10.1136/hrt.2009.190942 PMID: 20483891
2. Otto CM, Burwash IG, Legget ME, Munt BI, Fujioka M, Healy NL, et al. Prospective study of asymptomatic valvular aortic stenosis. Clinical, echocardiographic, and exercise predictors of outcome. Circulation. 1997; 95: 2262-70. PMID: 9142003
3. Rosenhek R, Zilberszac R, Schemper M, Czerny M, Mundigler G, Graf S, et al. Natural history of very severe aortic stenosis. Circulation. 2010; 121: 151-6. doi: 10.1161/CIRCULATIONAHA.109.894170
4. Vahanian A, Alfieri O, Andreotti F, Antunes MJ, Baron-Esquivias G, Baumgartner H, et al. Guidelines on the management of valvular heart disease (version 2012): The Joint Task Force on the Management of Valvular Heart Disease of the European Society of Cardiology (ESC) and the European Association for Cardio-Thoracic Surgery (EACTS). Eur Heart J. 2012; 33: 2451-96. doi: 10.1093/eurheartj/ehs109 PMID: 22922415
5. Nishimura RA, Otto CM, Bonow RO, Carabello BA, Erwin JP 3rd, Guyton RA, et al. 2014 AHA/ACC Guideline for the Management of Patients With Valvular Heart Disease: A Report of the American Collegof Cardiology/American Heart Association Task Force on Practice Guidelines. Circulation. 2014; 129: 2440-92. doi: 10.1161/CIR.0000000000000029 PMID: 24589852
6. Lancellotti P, Moonen M, Magne J, O'Connor K, Cosyns B, Attena E, et al. Prognostic effect of longaxis left ventricular dysfunction and B-type natriuretic peptide levels in asymptomatic aortic stenosis. Am J Cardiol. 2010; 105: 383-8. doi: 10.1016/j.amjcard.2009.09.043 PMID: 20102953
7. Lim P, Monin JL, Monchi M, Garot J, Pasquet A, Hittinger L, et al. Predictors of outcome in patients with severe aortic stenosis and normal left ventricular function: role of B-type natriuretic peptide. Eur Heart J. 2004; 25: 2048-53. PMID: 15541842
8. Bergler-Klein J, Klaar U, Heger M, Rosenhek R, Mundigler G, Gabriel H, et al. Natriuretic peptides predict symptom-free survival and postoperative outcome in severe aortic stenosis. Circulation. 2004; 109: 2302-8. PMID: 15117847
9. Monin JL, Lancellotti P, Monchi M, Lim P, Weiss E, Piérard L, et al. Risk score for predicting outcome in patients with asymptomatic aortic stenosis. Circulation. 2009; 120: 69-75. doi: 10.1161/ CIRCULATIONAHA.108.808857 PMID: 19546391
10. Kakkar R, Lee RT. The IL-33/ST2 pathway: therapeutic target and novel biomarker. Nat Rev Drug Discov. 2008; 7: 827-40. doi: 10.1038/nrd2660 PMID: 18827826
11. Sanada S, Hakuno D, Higgins LJ, Schreiter ER, McKenzie AN, Lee RT. IL-33 and ST2 comprise a critical biomechanically induced and cardioprotective signaling system. J Clin Invest. 2007; 117: 1538-49. PMID: 17492053
12. Sawada H, Naito Y, Hirotani S, Akahori H, Iwasaku T, Okuhara Y, et al. Expression of interleukin-33 and ST2 in nonrheumatic aortic valve stenosis. Int J Cardiol. 2013; 168: 529-31. doi: 10.1016/j.ijcard. 2012.12.059 PMID: 23332814
13. Shimpo N, Morrow D, Weinberg E, Sabatine M, Murphy S, Antman E, et al. Serum levels of the interleukin- 1 receptor family member ST2 predict mortality and clinical outcome in acute myocardial infarction. Circulation. 2004; 109: 2186-2190. PMID: 15117853
14. Sabatine MS, Morrow DA, Higgins LJ, MacGillivray C, Guo W, Bode C, et al. Complementary roles for biomarkers of biomechanical strain ST2 and N-terminal prohormone B-type natriuretic peptide in patients with ST-elevation myocardial infarction. Circulation. 2008; 117: 1936-44. doi: 10.1161/ CIRCULATIONAHA.107.728022 PMID: 18378613
15. Gruson D, Lepoutre T, Ahn SA, Rousseau MF. Increased soluble ST2 is a stronger predictor of longterm cardiovascular death than natriuretic peptides in heart failure patients with reduced ejection fraction. Int J Cardiol. 2014; 172: e250-2. doi: 10.1016/j.ijcard.2013.12.101 PMID: 24467978
16. Felker GM, Fiuzat M, Thompson V, Shaw LK, Neely ML, Adams KF, et al. Soluble ST2 in ambulatory patients with heart failure: Association with functional capacity and long-term outcomes. Circ Heart Fail. 2013; 6: 1172-9. doi: 10.1161/CIRCHEARTFAILURE.113.000207 PMID: 24103327
17. Ky B, French B, McCloskey K, Rame JE, McIntosh E, Shahi P, et al. High-sensitivity ST2 for prediction of adverse outcomes in chronic heart failure. Circ Heart Fail. 2011; 4: 180-7. doi: 10.1161/ CIRCHEARTFAILURE.110.958223 PMID: 21178018
18. Pascual-Figal DA, Ordoñez-Llanos J, Tornel PL, Vázquez R, Puig T, Valdés M, et al. MUSIC Investigators. Soluble ST2 for predicting sudden cardiac death in patients with chronic heart failure and left ventricular systolic dysfunction. J Am Coll Cardiol. 2009; 54: 2174-9. doi: 10.1016/j.jacc.2009.07.041 PMID: 19942089
19. Weinberg E, Shimpo M, Hurwitz S, Tominaga S, Rouleau J, Lee R. Identification of serum soluble ST2 receptor as a novel heart failure biomarker. Circulation. 2003; 107: 721-726. PMID: 12578875
20. Redfield MM, Rodeheffer RJ, Jacobsen SJ, Mahoney DW, Bailey KR, Burnett JC Jr. Plasma brain natriuretic peptide concentration: impact of age and gender. J Am Coll Cardiol. 2002; 40: 976-82. PMID: 12225726
21. Clavel MA, Malouf J, Michelena HI, Suri RM, Jaffe AF, Mahoney DW, et al. B-Type Natriuretic Peptide Clinical Activation in Aortic Stenosis. Impact on Long-Term Survival. J Am Coll Cardiol. 2014; 63: 2016-25. doi: 10.1016/j.jacc.2014.02.581 PMID: 24657652
22. Bartunek J, Delrue L, Van Durme F, Muller O, Casselman F, De Wiest B, et al. Nonmyocardial production of ST2 protein in human hypertrophy and failure is related to diastolic load. J Am Coll Cardiol. 2008; 52: 2166-74. doi: 10.1016/j.jacc.2008.09.027 PMID: 19095135
23. Demyanets S, Kaun C, Pentz R, Krychtiuk KA, Rauscher S, Pfaffenberger S, et al. Components of the interleukin-33/ST2 system are differentially expressed and regulated in human cardiac cells and in cells of the cardiac vasculature. J Mol Cell Cardiol. 2013; 60: 16-26. doi: 10.1016/j.yjmcc.2013.03.020 PMID: 23567618
24. Mildner M, Storka A, Lichtenauer M, Mlitz V, Ghannadan M, Hoetzenecker K, et al. Primary sources and immunological prerequisites for sST2 secretion in humans. Cardiovasc Res. 2010; 87: 769-777. doi: 10.1093/cvr/cvq104 PMID: 20363761
25. Shah RV, Chen-Tournoux AA, Picard MH, van Kimmenade RR, Januzzi JL. Serum levels of the interleukin- 1 receptor family member ST2, cardiac structure and function, and long-term mortality in patients with acute dyspnea. Circ Heart Fail. 2009; 2: 311-9. doi: 10.1161/CIRCHEARTFAILURE.108.833707 PMID: 19808354
26. Martínez-Martínez E, Miana M, Jurado-López R, Rousseau E, Rossignol P, Zannad F, et al. A role for soluble ST2 in vascular remodeling associated with obesity in rats. PLoS One. 2013; 8: e79176 doi: 10. 1371/journal.pone.0079176 PMID: 24265755
27. Henri C, Magne J, Dulgheru R, Davin L, Laaraibi S, Voilliot D, et al. Usefulness of serial B-type natriuretic peptide assessment in asymptomatic aortic stenosis. Am J Cardiol. 2014; 114: 441-8. doi: 10. 1016/j.amjcard.2014.04.053 PMID: 24948495
28. Henri C, Magne J, Dulgheru R, Laaraibi S, Voilliot D, Kou S, et al. Brain natriuretic peptide release in patients with aortic stenosis: resting and exercise echocardiographic determinants. Int J Cardiol. 2014; 172: 611-3. doi: 10.1016/j.ijcard.2014.01.084 PMID: 24502879